Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Cancer treatment with either standard chemotherapy or targeted agents often results in the
emergence of drug-refractory cell populations, ultimately leading to therapy failure. The …

We studied how intratumoral genetic heterogeneity shapes tumor growth and therapy
response for isocitrate dehydrogenase (IDH)-wild-type glioblastoma, a rapidly regrowing …

Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for
preclinical studies and therapeutic testing. It has been proposed that the mouse host affects …

Novel treatment options for metastatic colorectal cancer (CRC) are urgently needed to
improve patient outcome. Here, we screen a library of non-characterized small molecules …

Patient‐derived xenograft (PDX) models are widely used as preclinical cancer models and
are considered better than cell culture models in recapitulating the histological features …

Incomplete understanding of the metastatic process hinders personalized therapy. Here we
report the most comprehensive whole-genome study of colorectal metastases vs. matched …

Purpose: Immunotherapy with bispecific T-cell engagers has achieved striking success
against hematologic malignancies, but efficacy against solid tumors has been limited. We …

Hepatic metastasis is a clinical challenge for colorectal cancer (CRC). Senescent cancer
cells accumulate in CRC favoring tumor dissemination. Whether this mechanism progresses …

Tumorigenesis is associated with the development of a highly variable pattern of cellular
diversity, consequence of genetic and epigenetic diversification, followed by clonal selection …